Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer Disease: Intersocietal Recommendations for Their Appropriate Use in Switzerland.
Options
Publisher DOI
PubMed ID
40222353
Description
The association of Swiss Memory Clinics (SMC) provides intersocietal recommendations for the use of anti-amyloid monoclonal antibodies (mAbs) in Switzerland. The recommendations are the result of extensive interdisciplinary discussions in a group of Swiss dementia experts from August 2023 until December 2024. They reflect the opinion of all societies involved in the diagnosis and treatment of dementia patients in Switzerland. Special emphasis is given to aspects that are specific to the Swiss landscape, including recommendations for infrastructural and personnel standards for institutions aiming to administer anti-amyloid mAbs in Switzerland.
Date of Publication
2025
Publication Type
Article
Keyword(s)
Alzheimer
•
Antibody
•
Dementia
•
Switzerland
•
Treatment
Language(s)
en
Contributor(s)
Rouaud, Olivier | |
Lathuiliere, Aurelien | |
Allali, Gilles | |
Sollberger, Marc | |
Meyer-Heim, Tatjana | |
Monsch, Andreas U | |
Lövblad, Karl-Olof | |
Becker, Stefanie | |
Barro-Belaygues, Nadège | |
Popp, Julius | |
Bürge, Markus | |
Lindheimer, Kathrin | |
Gietl, Anton | |
Jung, Hans H | |
Georgescu, Dan | |
Meyer, Rafael | |
Frisoni, Giovanni B |
Additional Credits
Series
Neurodegenerative Diseases
Publisher
Karger Publishers
ISSN
1660-2862
1660-2854
Access(Rights)
metadata.only